FY2025 Earnings Estimate for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Lifesci Capital issued their FY2025 EPS estimates for Inhibikase Therapeutics in a report issued on Monday, December 1st. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics' current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics' Q4 2025 earnings at ($0.12) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.00) EPS.

Inhibikase Therapeutics Trading Down 6.0%

Inhibikase Therapeutics stock opened at $1.41 on Wednesday. The firm has a market cap of $106.00 million, a P/E ratio of -0.53 and a beta of 0.89. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $4.20. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.71.

Institutional Trading of Inhibikase Therapeutics

Several large investors have recently added to or reduced their stakes in IKT. Geode Capital Management LLC lifted its position in shares of Inhibikase Therapeutics by 228.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,066,700 shares of the company's stock worth $2,080,000 after purchasing an additional 741,940 shares during the period. ADAR1 Capital Management LLC raised its stake in Inhibikase Therapeutics by 2.5% in the third quarter. ADAR1 Capital Management LLC now owns 5,247,603 shares of the company's stock worth $8,501,000 after buying an additional 125,498 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Inhibikase Therapeutics by 277.7% in the first quarter. Goldman Sachs Group Inc. now owns 166,025 shares of the company's stock worth $364,000 after buying an additional 122,073 shares during the period. Jane Street Group LLC bought a new stake in Inhibikase Therapeutics during the 1st quarter valued at approximately $255,000. Finally, Citadel Advisors LLC bought a new stake in Inhibikase Therapeutics during the 3rd quarter valued at approximately $116,000. Institutional investors own 3.81% of the company's stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.

Recommended Stories

• Five stocks we like better than Inhibikase Therapeutics
• How to Invest in Biotech Stocks
• Palantir Stock Finds Its Footing—and a Path to Global Growth
• What Does a Stock Split Mean?
• The $100 Million Tell: Following Smart Money Into DoorDash
• Bank Stocks - Best Bank Stocks to Invest In
• Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inhibikase Therapeutics Right Now?

Before you consider Inhibikase Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.

While Inhibikase Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here